Retatrutide — Triple Agonist for Obesity

Research note by Tam — registered 2026-09-06. Related topic: black-market dupes of retatrutide flooding the gray market (BBC health feed 2026-09-04).

Summary

• Retatrutide is Eli Lilly's once-weekly injectable triple agonist (GIP / GLP-1 / glucagon receptors) in development for obesity — not FDA-approved as of last verification; current regulatory status needs a fresh check.
• Phase 2 (NEJM, Jun 2023, n=338 adults with obesity): mean weight loss of 24.2% at 48 weeks on the 12 mg dose vs 2.1% placebo — the deepest reported at that time.
• The Phase 3 TRIUMPH program is the decision point for approval; final efficacy/safety picture and filing timeline must be verified against current Lilly releases.

Key findings

• Clear dose-response at 48 weeks; top dose (12 mg) produced 24.2% mean weight loss, and more than 90% of that group achieved at least 5% loss.
• Secondary endpoints also improved: waist circumference, blood pressure, lipids, glycemic measures.
• Safety profile dominated by gastrointestinal events (nausea, diarrhea, vomiting), mostly mild-to-moderate and dose-dependent; no program-stopping signal identified.
• TRIUMPH-4 (obesity + knee osteoarthritis) topline reported positive by Lilly in 2025 — unverified in this note; confirm before citing.

Implications

• If Phase 3 results hold, retatrutide would set a new benchmark vs semaglutide (~15%) and tirzepatide (~21% at 72 weeks).
• Until approved, any non-trial supply is gray-market and unsafe — family should not source it.
• Action item: verify current TRIUMPH status and filing date before any family-facing recommendation.

Sources

• Jastreboff AM et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial," N Engl J Med 2023;389:514-526.
• Eli Lilly investor press releases (TRIUMPH program).
• clinicaltrials.gov — TRIUMPH Phase 3 registrations.